Trial Summary
What is the purpose of this trial?The investigators assess whether guanfacine extended release (GXR; 3mg/d) compared with placebo (PBO) will attenuate drinking and drinking-related factors in N=200 men and women with Alcohol Use Disorder (AUD) across 12-weeks.
Eligibility Criteria
This trial is for men and women with Alcohol Use Disorder (AUD) who are seeking treatment. Specific eligibility criteria details were not provided, so it's important to contact the study organizers for more information on who can participate.Inclusion Criteria
Provide informed verbal and written consent
Demonstrate a positive urine for alcohol on admission to study procedures
I am over 18 years old with a BMI between 18 and 35.
+5 more
Exclusion Criteria
Meet criteria for physiological dependence on alcohol requiring medical detoxification
Be pregnant or breast feeding
Meet criteria for moderate to severe SUD, excluding alcohol and nicotine
+7 more
Participant Groups
The trial is testing if Guanfacine Extended Release (GXR), at a dose of 3mg per day, helps reduce alcohol consumption over a period of 12 weeks compared to a placebo in 200 participants.
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Guanfacine Extended Release (XR)Experimental Treatment1 Intervention
Participants receive guanfacine XR, 3mg tablet orally, once per day for 12 weeks
Group II: PlaceboPlacebo Group1 Intervention
Participants receive guanfacine XR, placebo tablet orally, once per day for 12 weeks
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
The Stark Neuroscience Building (Goodman Hall)Indianapolis, IN
Rutgers School of Health ProfessionalsNewark, NJ
Loading ...
Who Is Running the Clinical Trial?
Indiana UniversityLead Sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)Collaborator